500k- 750k TD patients...Really?

Quote

anonymous

Guest
Best non-industry estimates peg the prevalence of TD patients to be at 200k patients. Neurocrine believes there are 500k-750k patients suffering from TD. While the side effect of TD represents a relevant unmet need... The number of patients suffering from it are relatively low. Consider that Teva is also ready to launch their own TD medication. This market place is not big enough to support two pharmaceutical companies and their sales forces. For any sales professionals considering a move to Neurocrine, make sure you take a hard look at Teva's product also. This is going to be a very risky marketplace to be in....
 






anonymous said:
Best non-industry estimates peg the prevalence of TD patients to be at 200k patients. Neurocrine believes there are 500k-750k patients suffering from TD. While the side effect of TD represents a relevant unmet need... The number of patients suffering from it are relatively low. Consider that Teva is also ready to launch their own TD medication. This market place is not big enough to support two pharmaceutical companies and their sales forces. For any sales professionals considering a move to Neurocrine, make sure you take a hard look at Teva's product also. This is going to be a very risky marketplace to be in....
Click to expand...
Thanks for the heads up, sales manager who doesn't want their reps jumping ship to Neurocrine...
 






i happen to agree. I don't think the market is large enough for the amount of reps they are hiring. And unless they have excellent market access, it's gonna be tough getting Rxs. Incidence is very low in anti-psychotic space. Perhaps neuro market has more potential?
 






Top Bottom
Back
Quote